New Folate Antagonist Drugs Portend Specific Treatment for Rheumatoid Arthritis
|
By LabMedica International staff writers Posted on 19 Jan 2009 |
|
Researchers have compared the efficacy of a group of folate antagonist drugs to methotrexate (MTX) the drug widely used for treatment of rheumatoid arthritis (RA).
Investigators at VU University Medical Center (Amsterdam, The Netherlands) were particularly interested in drugs that could enter cells by binding to the folate receptor FR-beta, which is primarily located on synovial cells. Methotrexate, on the other hand, enters cells through the reduced folate carrier (RFC) pathway, which is found on most cells in the body. The widespread distribution of RFC limits the usefulness of MTX because of adverse side effects and development of resistance to the drug.
In the current study, the investigators screened candidate drugs for their ability to bind to FR-beta. They employed immunohistochemistry and computer-assisted digital imaging analyses to detect FR-beta protein expression on immunocompetent cells in synovial biopsy samples from RA patients with active disease and in noninflammatory control synovial tissues. FR-beta messenger RNA (mRNA) levels were determined by reverse transcription-polymerase chain reaction (PCR) analysis.
Results published in the January 2009 issue of the journal Arthritis & Rheumatism revealed that immunohistochemical staining of RA synovial tissue indicated high expression of FR-beta on macrophages in the intimal lining layer and synovial sublining, whereas no staining was observed in T-cell areas or in control synovial tissue. Levels FR-beta mRNA were highest in synovial tissue extracts and RA monocyte-derived macrophages, but low in peripheral blood T-cells and monocytes. Screening of 10 new-generation folate antagonists revealed four compounds for which FR-beta had a high binding affinity (20-77-fold higher than for MTX). One of these, the thymidylate synthase inhibitor BCG 945, displayed selective targeting against FR-beta-transfected cells. BCG 945 was not taken up by through the FRC pathway.
The authors concluded that their results suggested, "Further evaluation of folate antagonists with properties of high binding affinity for FR-beta and low affinity for the RFC may pave the road for a more selective targeted therapy of activated synovial macrophages.”
Related Links:
VU University Medical Center
Investigators at VU University Medical Center (Amsterdam, The Netherlands) were particularly interested in drugs that could enter cells by binding to the folate receptor FR-beta, which is primarily located on synovial cells. Methotrexate, on the other hand, enters cells through the reduced folate carrier (RFC) pathway, which is found on most cells in the body. The widespread distribution of RFC limits the usefulness of MTX because of adverse side effects and development of resistance to the drug.
In the current study, the investigators screened candidate drugs for their ability to bind to FR-beta. They employed immunohistochemistry and computer-assisted digital imaging analyses to detect FR-beta protein expression on immunocompetent cells in synovial biopsy samples from RA patients with active disease and in noninflammatory control synovial tissues. FR-beta messenger RNA (mRNA) levels were determined by reverse transcription-polymerase chain reaction (PCR) analysis.
Results published in the January 2009 issue of the journal Arthritis & Rheumatism revealed that immunohistochemical staining of RA synovial tissue indicated high expression of FR-beta on macrophages in the intimal lining layer and synovial sublining, whereas no staining was observed in T-cell areas or in control synovial tissue. Levels FR-beta mRNA were highest in synovial tissue extracts and RA monocyte-derived macrophages, but low in peripheral blood T-cells and monocytes. Screening of 10 new-generation folate antagonists revealed four compounds for which FR-beta had a high binding affinity (20-77-fold higher than for MTX). One of these, the thymidylate synthase inhibitor BCG 945, displayed selective targeting against FR-beta-transfected cells. BCG 945 was not taken up by through the FRC pathway.
The authors concluded that their results suggested, "Further evaluation of folate antagonists with properties of high binding affinity for FR-beta and low affinity for the RFC may pave the road for a more selective targeted therapy of activated synovial macrophages.”
Related Links:
VU University Medical Center
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Pipet Controller
Stripettor Pro
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
Molecular Diagnostics
view channel
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
